Immunic, Inc.
IMUX
$1.12
-$0.03-2.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.85% | -3.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.37% | 12.76% | |||
| Operating Income | 0.37% | -12.76% | |||
| Income Before Tax | -3.31% | -13.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.31% | -13.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.31% | -13.98% | |||
| EBIT | 0.37% | -12.76% | |||
| EBITDA | 0.34% | -12.73% | |||
| EPS Basic | -3.91% | -13.97% | |||
| Normalized Basic EPS | -3.86% | -14.03% | |||
| EPS Diluted | -3.91% | -13.97% | |||
| Normalized Diluted EPS | -3.86% | -14.03% | |||
| Average Basic Shares Outstanding | -0.56% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.56% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||